Page 5 - Active Biotech News Today

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any natio...

Annual General Meeting of Active Biotech AB PRESS RELEASE The Annual General Meeting of Active Biotech was held on May 19, 2021. Due to the extraordinary situation as a result of the COVID-19 pandemic, the Meeting was carried out through postal voting, without any physical attendance. The following main resolutions were passed. In accordance with the Board of Directors proposal, it was resolved that no dividend would be paid for the financial year 2020, the Companys accumulated loss shall be ca...

Annual General Meeting of Active Biotech AB PRESS RELEASE The Annual General Meeting of Active Biotech was held on May 19, 2021. Due to the extraordinary situation as a result of the COVID-19 pandemic, the Meeting was carried out through postal voting, without any physical attendance. The following main resolutions were passed. In accordance with the Board of Directors’ proposal, it was resolved that no dividend would be paid for the financial year 2020, the Company’s accumulated loss shall...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Annual Report 2020 Active Biotech AB (publ) Active BiotechApril 22, 2021 GMT Active Biotech’s Annual Report 2020 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. Helén Tuvesson, CEO, tel. +46 46 19 21 56,  helen.tuvesson@activebiotech.com Hans Kolam, CFO, tel. +46 46 19 20 44, hans.kolam@activebiotech.com ADVERTISEMENT Scheelevägen...

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any natio...

Message : Required fields Phase IIa trial in non-small cell lung cancer expected to begin enrollment in the US in the second half of 2021 Lund Sweden, April 19, 2021 - Active Biotech AB (publ) (NASDAQ STOCKHOLM: ACTI) and NeoTX today announced that they have received clearance from the U.S. Food and Drug Administration (FDA) for the Investigational New Drug (IND) application of the tumor targeted superantigen naptumomab estafenatox (Naptumomab). The Phase IIa open label trial will evaluate na...

Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, 220 07 Lund, Sweden +46 46-19 20 00 www.activebiotech.com This information is information that Active Biotech AB is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the contact person set out above, at 08.30 a.m. CET on April 19, 2021. Active Biotech Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company that deploys its extensi...

* Not for trading, but in connection with the registration of American Depositary Shares, pursuant to the requirements of the Securities and Exchange Commission. Securities registered or to be registered pursuant to Section 12(g) of the Act: None None Indicate the number of outstanding shares of each of the issuers classes of capital or common stock as of the close of the period covered by the annual report: Title of each class Ordinary Shares, nominal...

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any natio...

Global Multiple Sclerosis Treatment market 11 Global Multiple Sclerosis Treatment market –Industry Trends and Forecast to 2028” focuses on the major drivers and restraints for the key players. These research report also provides Comprehensive analysis of the market share, segmentation, revenue forecasts and geographic regions of the market. Report is a professional and in-depth study on the current state of Industry. With 350 pages, 60 Figures And 220 Tables in it Global Multiple Sclerosi...